Retina

Topical Endoscopic Fundal Imaging (TEFI) offers a rapid, comprehensive and non-invasive method of monitoring retinal disease progression, according to a study published in the December issue of Investigative Ophthalmology and Visual Science.

Avastin (bevacizumab; Genentech) increases the ease of vitrectomy in severe proliferative diabetic retinopathy (PDR), according to a study published in the July issue of Clinical and Experimental Ophthalmology.

The lack of experience with evidence-based guidelines may be the reason for excessive follow-up after screening for hydroxychloroquine retinopathy, according to study results published in the December issue of the British Journal of Ophthalmology.

When using bevacizumab to treat choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD), a loading dose (LD) of bevacizumab is more effective than an as-needed (PRN) dosing schedule, according to study results published in the December issue of the British Journal of Ophthalmology.

Pegaptanib sodium therapy is safe in patients with neovascular age-related macular degeneration (NV-AMD) up to three years, according to study results published in the December issue of the British Journal of Ophthalmology.

It is possible to administer verteporfin and ranibizumab on the same day without adverse events, according to study results published in the December issue of the British Journal of Ophthalmology.

Until I see research to convince me otherwise, steroid therapy will continue to be my drug of choice.

25 G surgery offers enhanced patient comfort as well as faster postoperative recovery.

Problems with night vision correlate to an increase in the risk of symptoms of both the wet and dry forms of age-related macular degeneration (AMD), according to study results published in the November issue of Ophthalmology.

An antioxidant eye drop (OT-551, Othera) is being investigated to treat geographic atrophy in dry age-related macular degeneration (AMD).

The high incidence of side effects associated with steroids makes them a less favourable treatment option.

The slimmer design of 25 G instruments has left us exposed to an increased risk of complications and decreased surgical control.

The Phase I three-year feasibility study of the Argus II Retinal Implant for Retinitis Pigmentosa (RP) will be expanded to enrol more patients in Europe, according to an announcement from Second Sight Medical Products, the implant's manufacturer.

An ophthalmology network, aiming to prevent loss of vision across the country, has been established in Wales.

Ellex's 2RT, a Retina Regeneration Therapy, is safe and effective in the treatment of macular oedema (ME) secondary to diabetic retinopathy (DR), according to study results presented at this year's American Academy of Ophthalmology meeting.

Four new ophthalmic lasers and delivery devices have been unveiled by Lumenis at the meeting of the American Academy of Ophthalmology.

A Phase I trial of POT-4, a complement inhibitor in development for the treatment of age-related macular degeneration (AMD), have demonstrated that the agent is safe and well tolerated. The results were presented by Potentia Pharmaceuticals during the Retina Subspecialty Day at the meeting of the American Academy of Ophthalmology.

The Implantable Miniature Telescope (IMT) from VisionCare for end-stage age-related macular degeneration (AMD) maintains best-corrected visual acuity (BCVA) improvements to two years, according to results published in the November edition of the American Journal of Ophthalmology.

Long-term use of anti-vascular endothelial growth factor (VEGF) drugs should be treated with caution, as endogenous VEGF plays an important role in the maintenance of retina neuronal cells, according to study results published by PLoS ONE on November 3.

The 23-gauge system for pars plana vitrectomy offers greater postoperative comfort for the patient than does the standard 20-gauge system, according to a study published online ahead of print by the British Journal of Ophthalmology.

Interest in complement factor inhibition in the treatment of age-related macular degeneration (AMD) continues to gain momentum with two developers making separate announcements on progress with their AMD therapy hopefuls.

Dr Didier Ducournau explains how the technique he invented based on a mistaken assumption has been refined over the last 21 years.

The SERPING1 gene code influences the likelihood of developing age-related macular degeneration (AMD), according to study results published online ahead of print by The Lancet.

Dr Claus Eckardt discusses the alternative to anti-VEGF drugs, to be employed when other measures have failed.

A broad expression of the normally selectively-expressed photosensitive protein melanopsin in retinal ganglion cells can restore vision in mice with photoreceptor degeneration, as reported in a study published in the October 14 issue of the Proceedings of the National Academy of Sciences.

Vitrectomy should only be used for patients with diabetic macular oedema (DME) who also display signs of vitreomacular traction, according to study results published in the October issue of Eye.

iSONEP (sonepcizumab), Lpath, Inc's drug candidate for treating age-related macular degeneration (AMD), has been administered to the first patients in its Phase I trial.

QLT091001 (QLT Inc), a synthetic retinoid, has begun a Phase I safety study. The orally administered compound is designed to replace 11-cis-retinal, a part of the retinoid-rhodopsin cycle that is essential for visual function, in Leber's Congenital Amaurosis (LCA) sufferers.

Bevacizumab injections can improve vision in patients with diabetic macular oedema, according to study results published in the October 2008 issue of the journal Retina.

Visual acuity (VA) in age-related macular degeneration (AMD) patients may vary significantly between measurement sessions, according to study results published in the October 2008 issue of Investigative Ophthalmology & Visual Sciences.